Peerview Oncology & Hematology Cme/cne/cpe Audio Podcast
Bruce R. Korf, MD, PhD - Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 1:00:14
- More information
Informações:
Synopsis
Go online to PeerView.com/YBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable and progressive genetic disorder caused by a partial or complete loss of function of the NF1 tumor suppressor gene, resulting in elevated RAS-mitogen-activated protein kinase (RAS/MAPK) pathway signaling and the potential development of subsequent NF1-associated tumors. Given current breakthroughs, including the emergence of MEK inhibitors, the ongoing challenge is how to effectively employ modern therapeutics in the management of patients with NF1 tumors, particularly pediatric patients. This case-based video discussion, based on a PeerView live “Seminars & Practicum” CME event, will offer an expert-guided review of the challenges inherent to the management of NF1-associated tumors and provide practical guidance on state-of-the-art solutions and the role that MEK-targeting agents can play in patient management. Upon completion